Study Examines How Stress Effects Alzheimer's

Stress hormones appear to rapidly exacerbate the formation of brain lesions that are the hallmarks of Alzheimer's disease, according to researchers at UC Irvine. The findings suggest that managing stress and reducing certain medications prescribed for the elderly could slow down the progression of this devastating disease.

In a study with genetically modified mice, Frank LaFerla, professor of neurobiology and behavior, and a team of UCI researchers found that when young animals were injected for just seven days with dexamethasone, a glucocorticoid similar to the body's stress hormones, the levels of the protein beta-amyloid in the brain increased by 60 percent. When beta-amyloid production increases and these protein fragments aggregate, they form plaques, one of the two hallmark brain lesions of Alzheimer's disease. The scientists also found that the levels of another protein, tau, also increased. Tau accumulation eventually leads to the formation of tangles, the other signature lesion of Alzheimer's. The findings appear in this week's issue of the Journal of Neuroscience.
"It is remarkable that these stress hormones can have such a significant effect in such a short period of time," LaFerla said. "Although we have known for some time that higher levels of stress hormones are seen in individuals in the early stages of Alzheimer's, this is the first time we have seen how these hormones play such a direct role in exacerbating the underlying pathology of the disease."

Bipolar Disorder and Substance Abuse

The assessment, diagnosis and treatment of these disorders when they are co-occurring is extremely challenging. They require a clinician who is aware differential diagnosis and the complexity of treatment for this population.

Treatment considerations
BD, alcoholism, and SUD are chronic relapsing disorders that require a longterm treatment approach to ensure continuity of treatment between episodes. It is important to emphasize preventive and recovery issues. Self-help activities, including participation in dual-diagnosis self-help groups and consumer advocacy groups, such as the Depression and Bipolar Support Alliance (www.dbsalliance.org), should be considered.

Psychotherapy has a crucial role in the overall treatment of patients who present with multiple psychosocial needs and dysfunctions. Psychotherapy also has an essential role in cementing the therapeutic alliance, enhancing treatment and medication adherence, and addressing relapse prevention and recovery issues.

Michigan is moving towards a more intergrated treatment for mental illness and substance use disorders. The benefits of treating these disorders in an intergrated system has been documented to improve relapse rates and recovery.

Healthy Reframe

It seems to me that clients who have moved significantly in therapy live more intimately with their feelings of pain but also more vividly with their feelings of ecstasy; that anger is more clearly felt but so also is love; that fear is an experience they know more deeply but so is courage. And the reason that they can thus live fully in a wider range is that they have this underlying confidence in themselves as trustworthy instruments for encountering life.

– Carl Rogers

Mentally Ill Prisoner Dies In Jackson, Michigan

Timothy Joe Souders was determined to be mentally ill and a prisoner in Jackson, Michigan. He died after he was reported in restraints "agitated, disoriented and psychotic" report written by federal monitor assigned to scrutinize medical care for the prison. What a shame that this happened? Why was this inmate unable to receive the mental health treatment he needed? Are the guards educated about mental health symptoms? It is always easier to look back and say we could have, should have, would have....What the real question is how to we change policies, procedures and educate so this does NOT happen again.

Behaviors, Not ADHD Diagnosis, Predict Adolescents' Initial Substance Use

A small NIH-funded study that followed 12-to 14-year olds over four years suggests that specific behaviors can help predict which youth will begin to use tobacco, alcohol, or marijuana. Monique Ernst, M.D., Ph.D., of the NIMH Mood and Anxiety Disorders Program, and colleagues at the National Institute on Drug Abuse reported in the June issue of Pediatrics that aggression in early adolescence predicted initiation of tobacco and marijuana use, while impulsivity predicted initiation of alcohol use.

More aggression predicted initiation and use of more substances. However, diagnoses of attention-deficit/hyperactivity disorder (ADHD), with or without conduct disorder, or of ADHD with anxiety and depression did not predict which of the youth would begin to use substances. The distinction may help pediatricians and others to better focus prevention efforts on the adolescents who are most vulnerable to substance use.
Most studies of this age group have focused on substance use, abuse, and dependence already in progress. This study instead examined 78 adolescents before they had used any substances and followed them for four years, providing a window on risk and opportunities for prevention.

Ernst M, Luckenbaugh DA, Moolchan ET, Leff MK, Allen R, Eshel N, London ED, Kimes A. Behavioral Predictors of Substance-Use Initiation in Adolescents With and Without Attention-Deficit/Hyperactivity Disorder. Pediatrics 117 (6):2030-2039. June 2006.

Pharmacology of Personality Disorders

Pharmacology of Personality Disorders

By Joseph Triebwasser, MD and Larry J. Siever, MD, Psychiatric Times URL: http://www.psychiatrictimes.com/article/showArticle.jhtml?articleId=191000148
July 2006, Vol. XXIII, No. 8
If psychopharmacology sometimes feels like walking a fine line between undertreatment and overtreatment or between letting patients suffer and turning to medications as an "easy fix," then the psychopharmacology of personality disorders can feel like walking a tightrope without a net.
Unfortunately, the published literature is helpful only up to a point. There are not many peer-reviewed randomized controlled trials, given the prevalence and debilitating nature of some of the personality disorders. Studies have tended to be comparatively small and, especially in light of the chronic nature of much Axis II pathology, short in duration.1 Few, if any, trials have compared in size and scope to the large government- or industry-funded studies of the major mood and psychotic disorders.
The studies that have been published often have had high dropout rates, with positive results limited to certain domains and other areas of disturbance largely unimproved.2 There also has been a growing trend, perhaps caused by liability or institutional review board concerns, for treatment studies to include only patients who are comparatively stable and free of active suicidality. Few recent personality disorder drug studies have included, for example, the intermittently unsafe borderline patients often seen in clinical practice. This means that there are virtually no randomized clinical trials of increasingly popular agents like topiramate, lamotrigine, or the atypical antipsychotic in borderline or other personality disordered patients who are or recently have been actively suicidal.
Nevertheless, meaningful strides have been made over the past several years, with several novel agents demonstrating statistically significant results. Most promising are major discoveries relating to neurobiologic abnormalities and neurobiologic changes in response to provocation or treatment that have helped elucidate the constitutional factors that underlie personality disturbance.3,4 Much of this recent outcome and neurobiologic research has focused on aspects or dimensions of the Axis II disorders in addition to or instead of the categoric syndromes defined by the DSM.
Personality disorders are phenotypic expressions of biologic vulnerabilities and arise from a combination of predisposing genotypes and experiential factors.5 These factors may consist of present-day life stressors and/or early abuse and neglect, the effects of all of which may be modulated by damage to the CNS as it develops during childhood and adulthood.6 Although the strong correlation between negative life experiences and personality disorders has become a cornerstone of our understanding of some Axis II pathology, it should be remembered that heredity also appears to play a crucial role in the pathogenesis of personality disorders.
A Norwegian twin study suggested that personality disorders are more strongly determined by genetics than are almost all the Axis I disorders.7 Moreover, the psychological damage caused by abuse and neglect may be modulated by deleterious effects on the "hard-wiring" of the CNS.8 It should not, therefore, be surprising that many patients with personality disorders exhibit structural and functional brain abnormalities, or that certain medications may be beneficial in these disorders.
Borderline personality disorder
By far the most studied personality disorder, borderline personality disorder (BPD), is also the only one to be the subject of an American Psychiatric Association practice guideline.9 Pioneering BPD studies that suggested the utility of neuroleptics and mood stabilizers, as well as the risks of benzodiazepines and tricyclic antidepressants, are by now well known.10,11 Early neurobiologic research implicated disturbances of the serotonin system in the suicidality and impulsive aggression characteristics of this population.12,13 Currently, the best validated medications for BPD may be the selective serotonin reuptake inhibitors (SSRIs)/serotonin-norepinephrine reuptake inhibitors (SNRIs), antipsychotics, and anticonvulsants.
In placebo-controlled trials, fluoxetine has been shown to be helpful with anger,14 irritability, aggression, and overall clinical status,15 although it did not appear to benefit patients receiving concurrent dialectical behavior therapy (DBT)16 and was less efficacious than olanzapine or the olanzapine-fluoxetine combination for depression and impulsivity-aggression.17 In a rare pharmacologic study using decreases in suicide attempts as the principal outcome measure, paroxetine was superior to placebo in a mixed sample of multiple attempters, the majority of whom had BPD.18 Both sertraline and citalopram were found to decrease the frequency of BPD—and of several other personality disorders—in patients entered into a randomized, non–placebo-controlled depression treatment study.19 Most recently, fluvoxamine was better than placebo for rapid mood shifts in BPD but not for impulsivity or aggression.20
Exploration of serotonergic abnormalities has continued to dominate neurobiologic research into BPD and its component dimensions. Trait impulsivity in persons with personality disorders has been associated with blunted hormonal responses to the serotonergic probe ipsapirone.21 Positron emission tomography (PET) scans of patients who have personality disorders with impulsive aggression have shown blunted metabolic responses to fenfluramine in the orbitofrontal, adjacent ventromedial, and cingulate cortices.22 Fluoxetine treatment of BPD in a sample of patients with impulsive aggression was associated not only with clinical improvement but with PET findings of increased metabolic rate in the orbitofrontal cortex.23
During the first wave of pharmacologic research in BPD, neuroleptics were among the most consistently efficacious agents, although follow-up studies to one famous set of trials failed to support haloperidol's overall usefulness.24,25 Two important studies demonstrated a decrease in suicide attempts or self-harm behaviors with depot neuroleptics.26,27 Unsurprisingly, atypical antipsychotics have supplanted neuroleptics in more recent research. Olanzapine has proved better than placebo on scales of anxiety, paranoia, anger/ hostility, and interpersonal sensitivity, although not depression28; overall clinical status29; and—when added to DBT—depression, anxiety, and impulsive aggression.30 More recently, aripiprazole was found to be superior to placebo for depression, anxiety, anger, and most of the domains measured by the SCL-90-R.31 The (partial) efficacy of antipsychotics in BPD may reflect underlying causative abnormalities of the dopaminergic system.32
Anticonvulsants have proved attractive to clinicians and researchers working with BPD because of the disorder's resemblance, in certain respects, to bipolar disorder, and because BPD patients' "anger attacks" sometimes seem seizure-like in their suddenness and irresistibility. Early encouraging results with carbamazepine10 were followed by a published trial in which the active drug showed no greater efficacy than placebo. 33 In a controlled study of the effect of divalproex on aggression, the intent-to-treat analysis failed to reveal any significant benefit, but subgroups with cluster B personality disorders34 and BPD35 showed improvements on various measures of anger, aggression, and overall clinical status. Divalproex has also been associated with amelioration of interpersonal sensitivity, anger/hostility, and aggression in BPD patients with comorbid bipolar II disorder.36
Newly popular anticonvulsants for BPD include lamotrigine and topiramate, both of which have been associated with decreases in self-report measures of anger in BPD patients.37-39 A recent topiramate study is noteworthy among BPD drug trials for using an usually broad range of outcome measures. Significant treatment-associated improvements were noted in somatization, interpersonal sensitivity, anxiety, hostility, phobic anxiety, and global severity on the SCL-90-R; 4 of 8 scales of the Inventory of Interpersonal Problems; and all 8 scales of the SF-36 Health Survey, an instrument measuring health-related quality of life.40
Innovative, recently studied agents to treat BPD include ethyl-eicosapentaenoic acid, which sometimes is used for bipolar and other mood disorders, and was found to be superior to placebo at reducing aggression and the severity of depressive symptoms in BPD.41 Two different doses of the -adrenergic agonist, clonidine, were given to BPD patients experiencing strong urges to engage in self-injurious behavior; both were associated with significant decreases in dissociative symptoms, suicidal ideation, and wishes to commit self-harm.42
Intravenous naloxone, in the only published placebo-controlled trial of an opiate antagonist known to us, appeared to reduce dissociative symptoms but failed to show greater efficacy than placebo.13 Nevertheless, BPD treatments that mimic or block narcotic activity show some promise. Many BPD patients mutilate themselves or engage in other behaviors like bulimia and substance abuse that also may reflect abnormalities of the endogenous opiate system. BPD patients who self-mutilate have shown diminished pain sensitivity,44,45 which, in turn, has been correlated with dissociation.46 Interestingly, responders to therapy for BPD show normalization of previously impaired nociception.47 It may be that physical self-destructiveness, impulsivity, and dissociation in BPD represent the final pathways of various possible disturbances in the painprocessing system, and that medications that help offset these disturbances will provide substantial benefit.
Schizotypal personality disorder
As with schizophrenia, functional impairment in schizotypal personality disorder (SPD) may be due more to patients' social withdrawal and cognitive abnormalities than to their odd beliefs and perceptual experiences. Several early BPD pharmacologic studies included persons with SPD and found little difference in medication responsiveness between the 2 groups. Unfortunately, little randomized research has been undertaken in the intervening years. One exception is a placebo- controlled study using low-dose risperidone that found significant treatment-associated improvements in both positive and negative symptoms.48 Promising agents for schizophrenia-spectrum disorders include drugs that enhance executive function, for example, through potentiating effects on noradrenergic neurons with termini in the prefrontal cortex or through prefrontal D1 agonism.
Antisocial personality disorder
Randomized studies in antisocial personality disorder have generally focused on forensic populations, often male prison inmates. Published research of this type has all but disappeared during the last 10 years, perhaps because of regulatory obstacles to enrolling prisoners in drug trials. In older studies, both lithium49,50 and phenytoin51,52 were found to be useful in decreasing aggression and/or rule infractions in incarcerated violent offenders.
Avoidant personality disorder
Of all the interrelationships between Axis I and Axis II disorders, one of the most widely agreed on is the close resemblance between social anxiety disorder and avoidant personality disorder (APD).53 In a controlled trial, a monoamine oxidase inhibitor (MAOI) was shown to be useful for social anxiety and, perhaps more strongly, for maladaptive personality traits, with a twothirds reduction in the number of brofaromine-treated patients who met criteria for APD.54
Polypharmacy in personality disorders
Despite the inconclusive evidence at present for the effectiveness of pharmacotherapy for the treatment of many personality disorders, patients with Axis II pathology, especially BPD, are among the most likely populations to be prescribed psychotropic drugs, often several simultaneously.55-57 The only combined therapy that has been tested in BPD, to our knowledge, is the olanzapine-fluoxetine combination, which was found not to be superior to olanzapine alone for depressive symptoms and impulsive aggression, although it did result in less weight gain.17
In our experience, polypharmacy in BPD frequently occurs as the result of a cumulative process: medications with unclear benefits continue to be prescribed for fear of inducing a clinical deterioration in a worrisome patient, while more and more medications are added on because of persistent symptomatology. Clinicians treating patients with BPD and other personality disorders should be on guard against this unwitting polypharmacy, since it is of little empirically supported usefulness and may result in exposing a vulnerable population to dangerous iatrogenic complications.
Axis I-Axis II comorbidity
One common approach to patients with personality disorders with comorbid mood or anxiety disorders can be summarized as, "medicate the Axis I symptoms and leave the Axis II problems for psychotherapy." In many clinicians' experience, however, including our own, pharmacologic treatments for mood or anxiety disorders tend to work less well in patients with severe personality disorders.
This is a controversial area, with some published research suggesting that Axis II pathology worsens the response to medication treatment of Axis I disorders and other studies suggesting that it does not. However, most of the relevant studies have excluded the sickest personality-disturbed patients (eg, ones who were suicidal), or else required that the Axis I disorder be the primary diagnosis, thereby excluding patients who were judged to be personality disturbed with a superimposed mood or anxiety disorder.
Recommendations and future directions
Much research remains to be done on personality disorder pharmacotherapy, especially neurobiologic explorations of underlying causes and risk factors. It is imperative that there be larger and longer randomized drug treatment trials, in both healthier and sicker populations, including studies in patients at risk for homicide or suicide. In view of the comparatively limited evidence for the efficacy of medications for Axis II pathology, as well as the marked placebo-responsiveness of some personality disordered patients, it seems both ethical and necessary for there to be further placebo-controlled trials, or at least trials with substantial placebo lead-in periods.
For clinicians treating patients with personality disorders, many medication options are available. In BPD, the bestsubstantiated choices include SSRIs/ SNRIs, anticonvulsants, and neuroleptics/atypical antipsychotics. Most of these drug classes have shown statistically significant benefits for aggression, anger, impulsivity, and/or affective lability, although results have been somewhat inconsistent.
There is evidence that atypical antipsychotics may be helpful for both positive and negative symptoms in SPD and that MAOIs may be a treatment for APD. Aggressiveness in antisocial personality disorder (ASPD) may be reduced by phenytoin or lithium, and it seems reasonable to infer that agents useful in treating aggressiveness in BPD may be useful in ASPD as well, especially given the high rates of comorbidity between the disorders.58
It is worthwhile to bear in mind that the extreme, dysregulated emotions to which patients with personality disorder are prone are likely to influence their attitudes toward medications. Treaters should expect certain persons with personality disorders, especially those with BPD, to alternate between idealizing the miraculous potential of medications and devaluing them as not worth taking or even considering.
An important pitfall to avoid is fostering in Axis II patients an overly optimistic conviction that a medication "cure" is just around the corner and that it is just a matter of finding "the right drug." Although it is reasonable to encourage patients to participate in rational medication trials, treaters should simultaneously encourage them to participate in evidence-based psychotherapy and to make efforts to sustain their realworld functioning, regardless of whether or not a given medication trial is successful. At the present time, there is little evidence that the difficulties experienced by persons with personality disorders will go into remission as a result of pharmacotherapy. Fully effective medication treatments for these widespread and often crippling disorders must await further descriptive and empirical research.
Dr Triebwasser is a research fellow affiliated with the Bronx, NY, VA Medical Center and the Mount Sinai School of Medicine. He reports that he has no conflicts of interest concerning the subject matter of this article.
Dr Siever is the director of the Special Evaluation Program for Mood and Personality Disorders and is a professor of psychiatry at the Mount Sinai School of Medicine. He is also director of the Bronx VA Mental Illness Research, Education, and Clinical Center. He reports that he has no conflicts of interest concerning the subject matter of this article.
Drugs Mentioned in This Article
Aripiprazole (Abilify)Brofaromine (Consonar)Carbamazepine (Carbatrol, Tegretol, others)Citalopram (Celexa)Clonidine (Catapres)Divalproex (Epival, Depakote)Ethyl-eicosapentaenoic acidFenfluramine (Pondimin)Fluoxetine (Prozac)Fluvoxamine (Luvox)Haloperidol (Haldol)IpsapironeLamotrigine (Lamictal)Lithium (Eskalith)Naloxone (Narcan, Suboxone, Pentazocine)Olanzapine (Zyprexa)Paroxetine (Paxil)Phenytoin (Dilantin)Risperidone (Risperdal)Sertraline (Zoloft)Topiramate (Topamax)
References
1.Binks CA, Fenton M, McCarthy L, et al. Pharmacological interventions for people with borderline personality disorder. Cochrane Database Syst Rev. 2006;CD005653. 2.Paris J. Recent advances in the treatment of borderline personality disorder. Can J Psychiatry. 2005;50:435-441. 3. Goodman M, New A, Siever L. Trauma, genes, and the neurobiology of personality disorders. Ann N Y Acad Sci. 2004;1032:104-116. 4. Siever LJ. Endophenotypes in the personality disorders. Dialogues Clin Neurosci. 2005;7:139-151. 5. Siever LJ, Davis KL. A psychobiological perspective on the personality disorders. Am J Psychiatry. 1991;148:1647-1658. 6. Heim C, Nemeroff CB. Neurobiology of early life stress: clinical studies. Semin Clin Neuropsychiatry. 2002;7:147-159. 7. Torgersen S, Lygren S, Oien PA, et al. A twin study of personality disorders. Compr Psychiatry. 2000;41:416-425. 8. Teicher MH, Andersen SL, Polcari A, et al. The neurobiological consequences of early stress and childhood maltreatment. Neurosci Biobehav Rev. 2003;27:33-44. 9. American Psychiatric Association Practice Guidelines. Practice guideline for the treatment of patients with borderline personality disorder. Am J Psychiatry. 2001;158(suppl):1-52. 10. Cowdry RW, Gardner DL. Pharmacotherapy of borderline personality disorder: alprazolam, carbamazepine, trifluoperazine, and tranylcypromine. Arch Gen Psychiatry. 1988;45:111-119. 11. Soloff PH, George A, Nathan S, et al. Amitriptyline versus haloperidol in borderlines: final outcomes and predictors of response. J Clin Psychopharmacol. 1989;9:238-246. 12. Traskman L, Asberg M, Bertilsson L, Sjostrand L. Monoamine metabolites in CSF and suicidal behavior. Arch Gen Psychiatry. 1981;38:631-636. 13. Coccaro EF, Siever LJ, Klar HM, et al. Serotonergic studies in patients with affective and personality disorders: correlates with suicidal and impulsive aggressive behavior. Arch Gen Psychiatry. 1989; 46:587-599. 14. Salzman C, Wolfson AN, Schatzberg A, et al. Effect of fluoxetine on anger in symptomatic volunteers with borderline personality disorder. J Clin Psychopharmacol. 1995;15:23-29. 15. Coccaro EF, Kavoussi RJ. Fluoxetine and impulsive aggressive behavior in personality-disordered subjects. Arch Gen Psychiatry. 1997;54:1081-1088. 16. Simpson EB, Yen S, Costello E, et al. Combined dialectical behavior therapy and fluoxetine in the treatment of borderline personality disorder. J Clin Psychiatry. 2004;65:379-385. 17. Zanarini MC, Frankenburg FR, Parachini EA. A preliminary, randomized trial of fluoxetine, olanzapine, and the olanzapine-fluoxetine combination in women with borderline personality disorder. J Clin Psychiatry. 2004;65:903-907. 18. Verkes RJ, Van der Mast RC, Hengeveld MW, et al. Reduction by paroxetine of suicidal behavior in patients with repeated suicide attempts but not major depression. Am J Psychiatry. 1998;155:543-547. 19. Ekselius L, Von Knorring L. Changes in personality traits during treatment with sertraline or citalopram. Br J Psychiatry. 1999;174:444-448. 20. Rinne T, van den Brink W, Wouters L, van Dyck R. SSRI treatment of borderline personality disorder: a randomized, placebo-controlled clinical trial for female patients with borderline personality disorder. Am J Psychiatry. 2002;159:2048-2054. 21. Minzenberg MJ, Grossman R, New AS, et al. Blunted hormone responses to ipsapirone are associated with trait impulsivity in personality disorder patients. Neuropsychopharmacology. 2006;31:197-203. 22. Siever LJ, Buchsbaum MS, New AS, et al. d,lfenfluramine response in impulsive personality disorder assessed with [18F]fluorodeoxyglucose positron emission tomography. Neuropsychopharmacology. 1999;20:413-423. 23. New AS, Buchsbaum MS, Hazlett EA, et al. Fluoxetine increases relative metabolic rate in prefrontal cortex in impulsive aggression. Psychopharmacology (Berl). 2004;176:451-458. 24. Cornelius JR, Soloff PH, Perel JM, Ulrich RF. Continuation pharmacotherapy of borderline personality disorder with haloperidol and phenelzine. Am J Psychiatry. 1993;150:1843-1848. 25. Soloff PH, Cornelius J, George A, et al. Efficacy of phenelzine and haloperidol in borderline personality disorder. Arch Gen Psychiatry. 1993;50:377-385. 26. Montgomery SA, Montgomery D. Pharmacological prevention of suicidal behavior. J Affect Disord. 1982;4:291-298. 27. Battaglia J, Wolff TK, Wagner-Johnson DS, et al. Structured diagnostic assessment and depot fluphenazine treatment of multiple suicide attempters in the emergency department. Int Clin Psychopharmacol. 1999;14:361-372. 28. Zanarini MC, Frankenburg FR. Olanzapine treatment of female borderline personality disorder patients: a double-blind, placebo-controlled pilot study. J Clin Psychiatry. 2001;62:849-854. 29. Bogenschutz MP, George Nurnberg H. Olanzapine versus placebo in the treatment of borderline personality disorder. J Clin Psychiatry. 2004;65:104-109. 30. Soler J, Pascual JC, Campins J, et al. Doubleblind, placebo-controlled study of dialectical behavior therapy plus olanzapine for borderline personality disorder. Am J Psychiatry. 2005;162:1221-1224. 31. Nickel MK, Muehlbacher M, Nickel C, et al. Aripiprazole in the treatment of patients with borderline personality disorder: a double-blind, placebocontrolled study. Am J Psychiatry. 2006;163:833-838. 32. Friedel RO. Dopamine dysfunction in borderline personality disorder: a hypothesis. Neuropsychopharmacology. 2004;29:1029-1039. 33. de la Fuente JM, Lotstra F. A trial of carbamazepine in borderline personality disorder. Eur Neuropsychopharmacol. 1994;4:479-486. 34. Hollander E, Tracy KA, Swann AC, et al. Divalproex in the treatment of impulsive aggression: efficacy in cluster B personality disorders. Neuropsychopharmacology. 2003;28:1186-1197. 35. Hollander E, Swann AC, Coccaro EF, et al. Impact of trait impulsivity and state aggression on divalproex versus placebo response in borderline personality disorder. Am J Psychiatry. 2005;162:621-624. 36. Frankenburg FR, Zanarini MC. Divalproex sodium treatment of women with borderline personality disorder and bipolar II disorder: a double-blind placebo-controlled pilot study. J Clin Psychiatry. 2002;63:442-446. 37. Nickel MK, Nickel C, Mitterlehner FO, et al. Topiramate treatment of aggression in female borderline personality disorder patients: a double-blind, placebo-controlled study. J Clin Psychiatry. 2004;65:1515-1519. 38. Nickel MK, Nickel C, Kaplan P, et al. Treatment of aggression with topiramate in male borderline patients: a double-blind, placebo-controlled study. Biol Psychiatry. 2005;57:495-499. 39. Tritt K, Nickel C, Lahmann C, et al. Lamotrigine treatment of aggression in female borderline-patients: a randomized, double-blind, placebo-controlled study. J Psychopharmacol. 2005;19:287-291. 40. Loew TH, Nickel MK, Muehlbacher M, et al. Topiramate treatment for women with borderline personality disorder: a double-blind, placebo-controlled study. J Clin Psychopharmacol. 2006;26:61-66. 41. Zanarini MC, Frankenburg FR. Omega-3 fatty acid treatment of women with borderline personality disorder: a double-blind, placebo-controlled pilot study. Am J Psychiatry. 2003;160:167-169. 42. Philipsen A, Richter H, Schmahl C, et al. Clonidine in acute aversive inner tension and self-injurious behavior in female patients with borderline personality disorder. J Clin Psychiatry. 2004;65:1414-1419. 43. Philipsen A, Schmahl C, Lieb K. Naloxone in the treatment of acute dissociative states in female patients with borderline personality disorder. Pharmacopsychiatry. 2004;37:196-199. 44. Russ MJ, Roth SD, Lerman A, et al. Pain perception in self-injurious patients with borderline personality disorder. Biol Psychiatry. 1992;32:501-511. 45. Schmahl C, Greffrath W, Baumgartner U, et al. Differential nociceptive deficits in patients with borderline personality disorder and self-injurious behavior: laser-evoked potentials, spatial discrimination of noxious stimuli, and pain ratings. Pain. 2004;110:470-479. 46. Kemperman I, Russ MJ, Shearin E. Self-injurious behavior and mood regulation in borderline patients. J Personal Disord. 1997;11:146-157. 47. Schmahl C. Neurobiology of BPD: an update. Presented at: Annual Meeting of the American Psychiatric Association; 2005; Atlanta. 48. Koenigsberg HW, Reynolds D, Goodman M, et al. Risperidone in the treatment of schizotypal personality disorder. J Clin Psychiatry. 2003;64:628-634. 49. Sheard MH. Effect of lithium on human aggression. Nature. 1971;230:113-114. 50. Sheard MH, Marini JL, Bridges CI, Wagner E. The effect of lithium on impulsive aggressive behavior in man. Am J Psychiatry. 1976;133:1409-1413. 51. Barratt ES, Kent TA, Bryant SG, Felthous AR. A controlled trial of phenytoin in impulsive aggression. J Clin Psychopharmacol. 1991;11:388-389. 52. Barratt ES, Stanford MS, Felthous AR, Kent TA. The effects of phenytoin on impulsive and premeditated aggression: a controlled study. J Clin Psychopharmacol. 1997;17:341-349. 53. Ralevski E, Sanislow CA, Grilo CM, et al. Avoidant personality disorder and social phobia: distinct enough to be separate disorders? Acta Psychiatr Scand. 2005;112:208-214. 54. Fahlen T. Personality traits in social phobia, II: changes during drug treatment. J Clin Psychiatry. 1995;56:569-573. 55. Sansone RA, Rytwinski D, Gaither GA. Borderline personality and psychotropic medication prescription in an outpatient psychiatry clinic. Compr Psychiatry. 2003;44:454-458. 56. Heinze M, Andreae D, Grohmann R. Pharmacotherapy of personality disorders in German speaking countries: state and changes in the last decade. Pharmacopsychiatry. 2005;38:201-205. 57. Makela EH, Moeller KE, Fullen JE, Gunel E. Medication utilization patterns and methods of suicidality in borderline personality disorder. Ann Pharmacother. 2006;40:49-52. 58. Becker DF, Grilo CM, Edell WS, McGlashan TH. Comorbidity of borderline personality disorder with other personality disorders in hospitalized adolescents and adults. Am J Psychiatry. 2000;157:2011-2016.
Evidence-based References
Koenigsberg HW, Reynolds D, Goodman M, et al. Risperidone in the treatment of schizotypal personality disorder. J Clin Psychiatry. 2003;64:628-634.
Nickel MK, Muehlbacher M, Nickel C, et al. Aripiprazole in the treatment of patients with borderline personality disorder: a double-blind, placebo-controlled study. Am J Psychiatry. 2006;163:833-838. .

Copyright © 2006 CMP Healthcare Media Group LLC

Interface Consultation Services Update

A brief overview of Interface Consultation Services current endeavors:

I. Blog Focus - We continue to post 2-3 times a week on ICS and Counseling Connections.

II. "High Risk Mental Health Emergenies" Book - Craig in the process of writing a book and he is in his second chapter. Go Craig!

III. PESI Seminars
Behavioral Managed Care - How to get what your clients Need.
High Risk Mental Health Emergencies - "How To" Techniques & Interventions
Clients in Crisis: Assess, Intervene and Succeed

IV. Telemental Health Triage - We continue our day-to-day service commitment to Riverwood Center to provide professional triage services so their consumers are assured efficient and timely access to mental health services, appropriate level of care assignments and expert telephone crisis triage.

V. MPRI - Michigan prisoner Re-entry initiative - ICS is discussing the possibility of being regional healthcare coordinators for the Southwest Michigan Region.

VI. Utilization Management opportunities - We continue to provide acute care preauthorization services for Riverwood Center and we are seeking other opportunities to expand these kinds of services to agencies in our region.

Suicide risk high with body image obsession

People with "body dysmorphic disorder" are 45 times more likely to commit suicide than people in the general population, a new study shows.

The findings underscore the importance of recognizing and treating this "often secretive" psychiatric disorder, Dr. Katherine A. Phillips, the study's co-author, told Reuters Health.
Individuals with body dysmorphic disorder, or BDD, have a distorted body image and think obsessively about their appearance, often for hours a day, explained Phillips, who is at Butler Hospital and Brown Medical School in Providence, Rhode Island.

The disorder frequently leads to self-loathing and social isolation, she added. It is not uncommon for people with BDD to tell no one about their condition, even a spouse or very close friends.

Studies have suggested that up to 2.4 percent of people have BDD, Phillips said. While most of us have concerns about appearance, she added, a person with BDD obsesses about these concerns and is virtually crippled by them. Phillips said. "It's easy to trivialize BDD, it's easy to confuse it with vanity," she added.

Most people with BDD can be helped by treatment with antidepressant drugs known as selective serotonin reuptake inhibitors, which include Prozac and Zoloft, or a type of counseling known as cognitive behavioral therapy, Phillips said.

"The good news is that there are two forms of treatment that seem to be helpful for most people with this disorder," she added. "This just underscores the importance of recognizing this illness and recognizing that it's a severe illness that can potentially respond very well to mental health treatment."

SOURCE: American Journal of Psychiatry, July 2006.

Self-Injury

Self-Injury is also termed self-mutilation, self-harm or self-abuse. The behavior is defined as the deliberate, repetitive, impulsive, non-lethal harming of one’s self. Self-injury includes: 1) cutting, 2) scratching, 3) picking scabs or interfering with wound healing, 4) burning, 5) punching self or objects, 6) infecting oneself, 7) inserting objects in body openings, 8) bruising or breaking bones, 9) some forms of hair-pulling, as well as other various forms of bodily harm. These behaviors, which pose serious risks, may by symptoms of a mental health problem that can be treated.

The effective treatment of self-injury is most often a combination of medication, cognitive/behavioral therapy, and interpersonal therapy, supplemented by other treatment services as needed. Medication is often useful in the management of depression, anxiety, obsessive-compulsive behaviors, and the racing thoughts that may accompany self-injury. Cognitive/behavioral therapy helps individuals understand and manage their destructive thoughts and behaviors. Contracts, journals, and behavior logs are useful tools for regaining self-control. Interpersonal therapy assists individuals in gaining insight and skills for the development and maintenance of relationships. Services for eating disorders, alcohol/substance abuse, trauma abuse, and family therapy should be readily available and integrated into treatment, depending on individual needs.

For further information regarding warning signs, incidence & onset, background of self-injurers, behavior patterns, reasons for behaviors, dangers, diagnoses, evaluation and treatment, go to Self-Injury Facts.

Privileged Teens and Increased Depression Rates

There's an epidemic among the affluent -- a 200 percent increase in depression among children in the upper classes, according to psychologist Madeline Levine.
Levine is the author of the recently published "The Price of Privilege: How Parental Pressure and Material Advantage are Creating a Generation of Disconnected and Unhappy Kids" (Harper Collins), and she recently spoke at the New Canaan Library and at Just Books Too in Greenwich.
"Affluent kids have three times the rate of depression, three times the rate of anxiety disorders and substantial rates of substance abuse and psychological disorders such as eating disorders and cutting than other socio-economic groups in the U.S.," she told the group of approximately 20 women who had come to hear her speak at the New Canaan Library. Later that evening, she spoke to a standing-room-only crowd at Just Books Too.

The book grew out of Levine's 25-year practice treating children and adolescents. About eight years ago Levine started seeing a change in her clients. In the past, young people in distress had an outward air of being frazzled, she said. Now the kids she was seeing looked good from the outside.

These children are overwhelmed by pressures that they and their family place on them. Depression effects all of us and as we can see it can be even more prevalent for those who push themselves and find their identity thorough performance instead of the finding an identity in being.

Substance Abuse and Mental Illness

Dr. David Mee-Lee presented recently in Southwestern Michigan to mental health professionals as Michigan attempts to integrate their mental health and substances abuse services. He addressed many of the attitudes and mispreceptions of mental health clinicians around substance use disorders. "That client has relapsed for the 3, 4, 5 X times there is nothing we can do for them." He compared this to a heart patient who has presented in the ER with his 3, 4, X times due to a heart attack or heart complications. We would never turn away the heart patient but people have turned away the chronic substance addicted patient. There is an element in freewill and lifestyle choice for both of these patients but their is also a genetic component as well that the patient has no control over. Michigan's move towards integration will assist the patients and clients with better care and also improve clinicians skills as well as reduce stigma and negative attitudes towards people with substance use disorders.